HEIDELBERG, Germany and GEMBLOUX, Belgium and SHANGHAI, China, July 21,
2024 /PRNewswire/ -- Full-Life Technologies, a
fully integrated global radiotherapeutics company, today announced
the appointment of Ted
Myles to Full-Life's Board of Directors. Mr. Myles will
serve as chairman of the audit committee and as a member of the
compensation committee of the Board.
"We are pleased to welcome Ted to Full-Life's Board of Directors
at this important time in the company's development. Ted has
extensive experience guiding biotechnology companies through all
stages of clinical development and commercialization and has been
very successful helping these companies access the capital they
need to advance their programs in service of patients in need,"
said Lanny
Sun, Co-founder, Chairman, and CEO of
Full-Life. "We welcome Ted to the board as we enter this
important phase in Full-Life's evolution, marked by significant
progress in both our pipeline and manufacturing facilities. Our
lead program, 225Ac-FL-020, has received Investigational
New Drug (IND) approval from the U.S. Food and Drug Administration
(FDA) for clinical trial in metastatic castration-resistant
prostate cancer (mCRPC) and was granted Fast Track Designation to
expedite clinical development pathway. Our manufacturing plant in
Belgium has received the nuclear
permit that allows us to conduct radioactive production once the
plant construction is completed. Recently, we have also sealed a
$571.5 million out-licensing deal
with SK Biopharmaceuticals who will further develop our FL-091
radiopharmaceutical compound into an innovative anti-cancer
treatment for global markets. These achievements underscore our
commitment to bringing life-saving therapies to patients worldwide.
I am excited to have Ted on our Board as we continue to execute on
our plan and move Full-Life forward."
"I am thrilled to join Full-Life's Board of Directors as the
company is about to initiate its global Phase I clinical trial for
its lead program 225Ac-FL-020. I look forward to working
with the team and sharing my experience and expertise to
successfully deliver promising therapies to the many patients who
are waiting for novel radiotherapies," said Mr. Myles.
Mr. Myles is an accomplished biotechnology executive with
three decades of deep financial and operational experience in
biotechnology and pharmaceuticals. He is currently the Chief
Operating Officer and Chief Financial Officer of Scholar Rock, a
late-stage biotechnology company focused on advancing innovative
treatments for spinal muscular atrophy, cardiometabolic disorders
and other serious diseases where protein growth factors play a
fundamental role. Mr. Myles has brought in more than half a billion
dollars of investment capital to support Scholar Rock's rich
pipeline during his tenure with the company. Prior to joining
Scholar Rock, Mr. Myles was the COO & CFO of AMAG
Pharmaceuticals, a commercial stage pharmaceutical company that was
acquired by Covis Pharmaceuticals. Before that, Mr. Myles was COO
& CFO of Ocata Therapeutics, a cell-therapy company that was
acquired by Astellas. Earlier in his career, Mr. Myles was an
investment banker in the healthcare group of SG Cowen Securities.
Mr. Myles holds an MBA from the Olin School of Business,
Washington University in St. Louis and a B.S.B.A. from the University of Hartford.
About Full-Life Technologies
Full-Life Technologies ("Full-Life") is a fully integrated
global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain
for radiopharmaceutical research & development, production
& commercialization to deliver clinical impact for patients.
The Company endeavors to tackle fundamental challenges affecting
radiopharmaceuticals today by pioneering innovative research that
will shape the treatments of tomorrow. We are comprised of a team
of fast-moving entrepreneurs and seasoned scientists with a proven
history of success in the life sciences, alongside radioisotope
research and clinical development.
View original
content:https://www.prnewswire.com/news-releases/full-life-technologies-announces-the-appointment-of-edward-ted-myles-to-its-board-of-directors-302202131.html
SOURCE Full-Life Technologies Limited